Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CCR6 | P51684 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31155681 | 0.85 | CCR6 (0.70) | LMNACCR6EPHX2ALDH1A1 | |
| SCHEMBL29264663 | 0.82 | GAA (0.58) | LMNACCR6EPHX2ALDH1A1 | |
| SCHEMBL31155674 | 0.80 | CCR6 (0.57) | LMNACCR6HTTEPHX2SMN1; SMN2 | |
| SCHEMBL31155671 | 0.80 | EPHX2 (0.59) | LMNACCR6HTTEPHX2TSHR | |
| SCHEMBL31155666 | 0.80 | CCR6 (0.48) | LMNACCR6EPHX2SMN1; SMN2TSHR | |
| SCHEMBL32670559 | 0.78 | CCR6 (0.49) | LMNACCR6HTTEPHX2SMN1; SMN2 | |
| SCHEMBL20772177 | 0.76 | TP53 (0.75) | USP5LMNAHTTEPHX2SMN1; SMN2 | |
| SCHEMBL23577993 | 0.75 | USP5 (0.58) | USP5LMNAHTTEPHX2SMN1; SMN2 | |
| SCHEMBL31106313 | 0.75 | CCR6 (0.75) | LMNACCR6EPHX2ALDH1A1 | |
| SCHEMBL32670563 | 0.74 | JAK2 (0.48) | LMNACCR6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034125-A1 | N-PHENYL-1-(PHENYLSULFONYL)PIPERIDIN-4-AMINE DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | USP5 2031/4885LMNA 1796/4885CCR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.